Daiichi Sankyo and Eli Lilly Submit Prasugrel NDA
Posted on: Monday, 7 January 2008, 03:00 CST
Daiichi Sankyo Company and Eli Lilly and Company have submitted a new drug application for prasugrel to the FDA for the treatment of patients with acute coronary syndrome who are managed with percutaneous coronary intervention, including coronary stenting.
According to the companies, if approved for marketing in the US, the trade name for prasugrel will be Effient.
Eli Lilly said that the new drug application (NDA) is based upon data from several trials, including the landmark triton-TIMI 38 (thrombolysis in myocardial infarction) clinical trial, which evaluated the safety and efficacy of prasugrel compared with clopidogrel (Plavix/Iscover) in reducing ischemic events such as non-fatal heart attack, non-fatal stroke and cardiovascular death in 13,608 patients.
Anthony Ware, Lilly vice president and cardiovascular/acute care platform leader for prasugrel, said: "We are elated and we feel confident in the strength and completion of this submission package, and plan to complete our submission in Europe in the first quarter of 2008. The benefit/risk profile of this compound, in comparison with the current standard of care, has the potential to improve outcomes for acute coronary syndrome patients undergoing percutaneous coronary intervention."
Source: Datamonitor
Related Articles
- D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
- D-Pharm Submits Investigational New Drug Application and Special Protocol Assessment to the FDA for Phase III Trial of DP-b99 in Acute Stroke Patients
- D-Pharm Announces Positive Phase IIb Trial Results for DP-B99 in Acute Stroke Patients
- D-Pharm Announces the Second Recommendation of an Independent Safety Monitoring Board to Continue the Phase II Study of DP-B99 in Acute Stroke Patients
- GSK's Arixtra Shows Promise in Acutely Ill Patients
- D-Pharm Announces the Recommendation of an Independent Safety Monitoring Board to Continue the Phase II Study of DP-B99 in Acute Stroke Patients
- Coronary Artery Dilation Among Patients Presenting With Systemic- Onset Juvenile Idiopathic Arthritis
- Noninvasive Diagnosis of Coronary Artery Disease in Patients With Diabetes By Dobutamine Stress Real-Time Myocardial Contrast Perfusion Imaging
- Off-Pump Coronary Artery Bypass in a Patient With the Antiphospholipid Syndrome
- Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes
 |
 |
User Comments (0)
RSS Feeds